A review on newly approved PARP inhibitors: Talazoparib and Olaparib
This project report is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2024.
Autor Principal: | Karim, Azrin |
---|---|
Outros autores: | Islam, Farzana |
Formato: | Project report |
Idioma: | English |
Publicado: |
Brac University
2024
|
Subjects: | |
Acceso en liña: | http://hdl.handle.net/10361/24372 |
Títulos similares
-
A review on potential of PARP inhibitors in the treatment of prostate cancer
por: Islam, Saidul
Publicado: (2022) -
Association of XRCC1 and XPD polymorphism with risk of prostate cancer in Bangladesh population
por: Ahmed, Nafisa
Publicado: (2023) -
SHP2 inhibitors: Recent advancements and potential breakthroughs in cancer therapy
por: Meem, Manila
Publicado: (2023) -
Mutation in DNA polymerase γ: mitochondrial disorders
por: Hossain, Sadman Sanjid
Publicado: (2023) -
RIPK pathway, as a potential target, for cancer treatment - a review
por: Jahan, Nusrat
Publicado: (2024)